[HTML] sciencedirect.com

[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel …

M Johnson, MC Garassino, T Mok, T Mitsudomi - Lung Cancer, 2022 - Elsevier
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
被引用次数：46 相关文章

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies

M Johnson, MC Garassino, T Mok… - Lung cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …
[HTML] lungcancerjournal.info

[HTML][HTML] Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel …

M Johnson, MC Garassino, T Mok… - Lung …, 2022 - lungcancerjournal.info
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.

M Johnson, MC Garassino, T Mok… - Lung Cancer …, 2022 - europepmc.org
Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …